20 results on '"Forman, Stephen J"'
Search Results
2. Acute Lymphoblastic Leukemia in the Older Adult.
- Author
-
Aldoss, Ibrahim, Forman, Stephen J., and Pullarkat, Vinod
- Subjects
- *
LYMPHOBLASTIC leukemia treatment , *THERAPEUTIC use of monoclonal antibodies , *PROTEIN-tyrosine kinase inhibitors , *LYMPHOBLASTIC leukemia diagnosis , *ELDER care , *CANCER chemotherapy , *DRUG resistance in cancer cells , *HEMATOPOIETIC stem cell transplantation , *IMMUNOTHERAPY , *LYMPHOBLASTIC leukemia , *PATIENT safety , *T cells , *TUMOR classification , *TREATMENT effectiveness , *THERAPEUTICS - Abstract
Acute lymphoblastic leukemia (ALL) in older adults presents a real challenge as a result of adverse disease biology and comorbidities that preclude delivering curative regimens. Conventional chemotherapy approaches have generally yielded unsatisfactory results in older patients with ALL as a result of excessive induction mortality, chemotherapy resistance of the leukemia, and the need to omit or dose reduce key drugs during the course of therapy because of adverse effects. Philadelphia chromosome–positive ALL represents about a quarter of newly diagnosed older adults, and the striking single-agent activity and excellent safety profile of tyrosine kinase inhibitors has allowed incorporation of these agents into therapy, significantly improving the outcome of older adults with Philadelphia chromosome–positive ALL. Allogeneic hematopoietic cell transplantation using reduced-intensity conditioning is a potentially curative approach in the older adult with ALL, and ironically, it may be better tolerated than intensive combination chemotherapy in a subset of older patients with ALL. Immunotherapies such as chimeric antigen receptor–modified T-cells, the bispecific T-cell–engaging antibody targeting CD19 (blinatumomab), and the antibody-drug conjugate targeting CD22 (inotuzumab) have shown safety and exceptional activity even in advanced ALL, and the efficacy of these agents has been observed irrespective of patient age. Several promising studies tailored specifically toward older adults with ALL are ongoing, with the majority of them incorporating novel immunotherapies, targeted therapies, or third-generation tyrosine kinase inhibitors into the front-line treatment regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma.
- Author
-
Armenian, Saro H., Mertens, Luc, Slorach, Cameron, Venkataraman, Kalyanasundaram, Mascarenhas, Kristen, Nathwani, Nitya, Wong, F. Lennie, Forman, Stephen J., and Bhatia, Smita
- Subjects
ANTHRACYCLINES ,LYMPHOMAS ,HEART failure ,HEART diseases ,BIOLOGICAL tags ,HEMATOPOIETIC stem cells ,HEART disease diagnosis ,HEART disease epidemiology ,LYMPHOMA treatment ,COMPARATIVE studies ,ECHOCARDIOGRAPHY ,HEMATOPOIETIC stem cell transplantation ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RISK assessment ,EVALUATION research ,DISEASE prevalence ,THERAPEUTICS - Abstract
Background: Anthracycline-related heart failure is a leading cause of morbidity in survivors of adult-onset lymphoma. There is a paucity of information on screening for late-occurring preclinical disease, which, in turn, has limited guidelines for early detection and intervention. The objectives of this study were to examine the prevalence and risk of cardiac dysfunction, as measured by echocardiography (abnormal left ventricular systolic/diastolic function or strain), in lymphoma survivors who received treatment with anthracyclines and to evaluate the diagnostic yield of blood biomarkers in the asymptomatic setting.Methods: Lymphoma survivors who underwent hematopoietic cell transplantation (HCT) (n = 78) or received conventional therapy (non-HCT; n = 77) were compared with each other and with a group of matched controls (n = 51); the study was limited to lymphoma survivors who were >5 years from diagnosis.Results: At a median follow-up of 9.4 years after diagnosis, 1 in 5 (20.6 %) lymphoma survivors had cardiac dysfunction; the odds of having cardiac dysfunction were 6.6-fold greater (odds ratio [OR], 6.6; P = .01) among lymphoma survivors compared with matched controls. There was a dose-dependent risk of cardiac dysfunction according to the cumulative anthracycline dose (controls [referent group], 1-249 mg/m2 [OR, 4.7; P = .05], and ≥250 mg/m2 [OR, 7.6; P < .01]), but there was no difference in the prevalence of cardiac dysfunction between conventionally treated and HCT survivors. The diagnostic accuracy of cardiac blood biomarkers in the asymptomatic setting was quite poor.Conclusions: In these long-term survivors, there was a high rate of cardiac dysfunction that was independent of HCT status. The growing number of lymphoma survivors makes it imperative to identify reliable and cost-effective strategies to decrease the burden of heart failure in this population. Cancer 2018;124:850-7. © 2017 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
4. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
- Author
-
Kharfan‐Dabaja, Mohamed A., Al Malki, Monzr M., Deotare, Uday, Raj, Renju V., El‐Jurdi, Najla, Majhail, Navneet, Cherry, Mohamad A., Bashir, Qaiser, Darrah, Justin, Nishihori, Taiga, Sibai, Hassan, Hamadani, Mehdi, Lima, Marcos, Gerds, Aaron T., Selby, George, Qazilbash, Muzaffar H., Forman, Stephen J., Ayala, Ernesto, Lipton, Jeffrey H., and Hari, Parameswaran N.
- Subjects
HEMATOLOGIC malignancies ,HEMATOPOIETIC stem cell transplantation ,DENDRITIC cells ,SURVIVAL analysis (Biometry) ,DISEASE remission ,THERAPEUTICS - Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is incurable with conventional therapies. Limited retrospective data have shown durable remissions after haematopoietic cell transplantation (HCT) [allogeneic (allo) or autologous (auto)]. We conducted a multicentre retrospective study in BPDCN patients treated with allo-HCT and auto-HCT at 8 centres in the United States and Canada. Primary endpoint was overall survival (OS). The population consisted of 45 consecutive patients who received an allo-HCT (n = 37) or an auto-HCT (n = 8) regardless of age, pre-transplant therapies, or remission status at transplantation. Allo-HCT recipients were younger (50 (14–74) vs. 67 (45–72) years, P = 0·01) and had 1-year and 3-year OS of 68% [95% confidence interval (CI) = 49–81%] and 58% (95% CI = 38–75%), respectively. Allo-HCT in first complete remission (CR1) yielded superior 3-year OS (versus not in CR1) [74% (95% CI = 48–89%) vs. 0, P < 0·0001]. Allo-HCT outcomes were not impacted by regimen intensity [3-year OS for myeloablative conditioning = 61% (95% CI = 28–83%) vs. reduced-intensity conditioning = 55% (95% CI = 28–76%)]. One-year OS for auto-HCT recipients was 11% (95% CI = 8–50%). These results demonstrate efficacy of allo-HCT in BPDCN, especially in patients in CR1. Pertaining to auto-HCT, our results suggest lack of efficacy against BPDCN, but this observation is limited by the small sample size. Larger prospective studies are needed to better define the role of HCT in BPDCN. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. RB but not R- HCVAD is a feasible induction regimen prior to auto- HCT in frontline MCL: results of SWOG Study S1106.
- Author
-
Chen, Robert W., Li, Hongli, Bernstein, Steven H., Kahwash, Samir, Rimsza, Lisa M., Forman, Stephen J., Constine, Louis, Shea, Thomas C., Cashen, Amanda F., Blum, Kristie A., Fenske, Timothy S., Barr, Paul M., Phillips, Tycel, Leblanc, Michael, Fisher, Richard I., Cheson, Bruce D., Smith, Sonali M., Faham, Malek, Wilkins, Jennifer, and Leonard, John P.
- Subjects
MANTLE cell lymphoma ,CANCER chemotherapy ,HEMATOPOIETIC stem cell transplantation ,DOXORUBICIN ,CANCER remission ,THERAPEUTICS - Abstract
Aggressive induction chemotherapy followed by autologous haematopoietic stem cell transplant (auto- HCT) is effective for younger patients with mantle cell lymphoma ( MCL). However, the optimal induction regimen is widely debated. The Southwestern Oncology Group S1106 trial was designed to assess rituximab plus hyper CVAD/ MTX/ ARAC (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate) ( RH) versus rituximab plus bendamustine ( RB) in a randomized phase II trial to select a pre-transplant induction regimen for future development. Patients had previously untreated stage III, IV, or bulky stage II MCL and received either 4 cycles of RH or 6 cycles of RB, followed by auto- HCT. Fifty-three of a planned 160 patients were accrued; an unacceptably high mobilization failure rate (29%) on the RH arm prompted premature study closure. The estimated 2-year progression-free survival ( PFS) was 81% vs. 82% and overall survival ( OS) was 87% vs. 88% for RB and RH, respectively. RH is not an ideal platform for future multi-centre transplant trials in MCL. RB achieved a 2-year PFS of 81% and a 78% MRD negative rate. Premature closure of the study limited the sample size and the precision of PFS estimates and MRD rates. However, RB can achieve a deep remission and could be a platform for future trials in MCL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.
- Author
-
Nguyen, Diana, Shayani, Sepideh, Palmer, Joycelynne, Dagis, Andrew, Forman, Stephen, Epstein, Joel, Spielberger, Ricardo, Nguyen, Diana T, and Forman, Stephen J
- Subjects
MUCOSITIS ,GRAFT versus host disease ,HEMATOPOIETIC stem cell transplantation ,DISEASE complications ,TOTAL body irradiation ,DISEASE incidence ,PREVENTION ,GROWTH factors ,ETOPOSIDE ,LENGTH of stay in hospitals ,PARENTERAL feeding ,QUALITY of life ,RADIOTHERAPY ,RETROSPECTIVE studies ,STOMATITIS ,THERAPEUTICS - Abstract
Purpose: The purpose of this study is to assess the impact of palifermin on oral mucositis (OM) and its sequelae in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) who were conditioned with fractionated total body irradiation (FTBI) and etoposide.Methods: This retrospective chart review study compared the effect of palifermin on the development of OM in patients who received this agent during an allo-HSCT (n = 99) to those who did not (n = 30). The primary end points were severity and duration of OM. Secondary end points included requirements for opioids, total parenteral nutrition (TPN), and intensive oral care; incidence of infection; length of hospital stay; and overall survival.Results: There was no significant difference in the incidence of all grades of OM, but incidence of severe OM was decreased in palifermin-exposed patients (34 vs 80 %, p < 0.0001). In patients who developed OM (all grades), the median duration of OM was shorter in palifermin-exposed patients (13 vs 18 days, p = 0.0001); there was no difference in the median duration of severe OM. Patients who received palifermin used less opioids and required a shorter duration of intensive oral care. There was no difference in duration of TPN, incidence of infection, length of hospital stay, and overall survival.Conclusions: Our findings demonstrated a significant benefit with the use of palifermin for allo-HSCT recipients who were conditioned with FTBI and etoposide. Palifermin can potentially improve quality of life for this patient population and reduce complications and resources used during the transplant process. A randomized clinical trial is required to confirm these results. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
7. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
- Author
-
Zain, Jasmine, Palmer, Joycelynne M., Delioukina, Maria, Thomas, Sandra, Tsai, Ni-Chun, Nademanee, Auayporn, Popplewell, Leslie, Gaal, Karl, Senitzer, David, Kogut, Neil, O'donnell, Margaret, and Forman, Stephen J.
- Subjects
HEMATOPOIETIC stem cell transplantation ,LYMPHOPROLIFERATIVE disorders ,DISEASE progression ,T-cell lymphoma ,MULTIVARIATE analysis ,THERAPEUTICS - Abstract
The study analyzed outcomes of a consecutive case series of 37 patients with peripheral T-cell non-Hodgkin lymphoma, from related and unrelated donors, using allogeneic hematopoietic cell transplant (allo-HCT), between the years 2000 and 2007. All patients were pretreated; the majority had either relapsed or progressive disease ( n == 25, 68%%), 13 had cutaneous histologies (CTCL), and all were ineligible for autologous transplant. Fully ablative conditioning regimens were used in 13 patients while 24 patients underwent reduced intensity conditioning (RIC). At 5 years the overall survival (OS) and progression-free survival (PFS) probabilities were 52.2%% and 46.5%%, respectively. At the time of analysis, nine (24.3%%) patients had either relapsed ( n == 6) or progressed ( n == 3) post allo-HCT. The cumulative incidences of relapse/progression and non-relapse mortality at 5 years were 24.3%% and 28.9%%. No statistically significant variables for survival or relapse were discovered by univariate Cox regression analysis of disease and patient characteristics; differences between CTCL and other histologies were not significant. The median follow-up of 64.0 months (range: 16.4--100.4) indicates a mature data-set with probable cure in the survivors. The relapse/progression curves reached and maintained plateaus after 1 year post-transplant, demonstrating that long-term disease control is possible after allo-HCT in patients with peripheral T-cell lymphoma with advanced disease. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
8. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation.
- Author
-
Choi, Michael, Can-Lan Sun, Kurian, Seira, Carter, Andrea, Francisco, Liton, Forman, Stephen J, Bhatia, Smita, and Sun, Can-Lan
- Subjects
HEMATOPOIETIC stem cell transplantation ,KIDNEY disease risk factors ,BLOOD diseases ,CYCLOSPORINE ,TACROLIMUS ,MULTIPLE myeloma diagnosis ,APLASTIC anemia treatment ,HEMATOLOGIC malignancies ,AUTOGRAFTS ,CHRONIC diseases ,COMPARATIVE studies ,HOMOGRAFTS ,KIDNEY diseases ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,EVALUATION research ,RELATIVE medical risk ,DISEASE incidence ,RETROSPECTIVE studies ,THERAPEUTICS - Abstract
Background: The authors investigated the risk of delayed chronic kidney disease (CKD) in 1190 adult hematopoietic cell transplantation (HCT) survivors who underwent HCT for hematologic malignancies or aplastic anemia between 1976 and 1997 and survived for at least 1 year.Methods: CKD was defined as a sustained elevation of serum creatinine that indicated a glomerular filtration rate of <60 mL per minute per 1.73 m2 for > or =3 months. The median age at HCT was 35 years (range, 18.1-68.6 years), and the median length of follow-up was 7.1 years after HCT (range, 1-24.3 years).Results: Sixty patients with CKD were identified, resulting in a cumulative incidence of 4.4% at 5 years (autologous HCT, 3.8%; matched-sibling HCT, 4.5%; unrelated donor HCT, 10%; P = .09 compared with autologous HCT). Older age at HCT (relative risk [RR] per 5-year increment, 1.33; 95% confidence interval [CI], 1.2-1.5), exposure to cyclosporine without tacrolimus (RR, 1.90; 95% CI, 1.1-3.4) or with tacrolimus (RR, 4.59; 95% CI, 1.8-11.5), and a primary diagnosis of multiple myeloma (RR, 2.51; 95% CI, 1.1-5.6) were associated with an increased risk of delayed CKD.Conclusions: In this study, the authors identified a subpopulation of patients who underwent HCT and remained at increased risk for CKD. The current findings set the stage for appropriate long-term follow-up of vulnerable patients. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
9. How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation.
- Author
-
Alvarnas, Joseph C., Zaia, John A., and Forman, Stephen J.
- Subjects
- *
THERAPEUTICS , *HIV infections , *HEMATOLOGIC malignancies , *HEMATOPOIETIC stem cell transplantation , *LYMPHOMA treatment , *CLINICAL trials , *NATURAL immunity , *PATIENTS - Abstract
Hematopoietic cell transplantation (HCT) has now been shown to be safe and effective for selected HIV-infected patients with hematological malignancies. Autologous HCT is now the standard of care for patients with HIV-related lymphomas who otherwisemeet standard transplant criteria. Limited data also support use of allogeneic HCT (alloHCT) in selected HIV-infected patients who meet standard transplant criteria. We recommend enrolling patients in clinical trials that offer access to CCR5Δ32 homozygous donors, if available. HIV-infected patients requiring HCT may also be considered for participation in trials evaluating the activity of gene-modified hematopoietic stem cells in conferring resistance to HIV infection. To be considered for HCT, patients must have HIV infection that is responsive to combination antiretroviral therapy (cART). Careful planning for the peri-HCT management of the cART can avoid risk of significant drug interactions and development of cART-resistant HIV. In general, we recommend against the use of boosted proteasome inhibitors and nonnucleotide reverse transcriptase inhibitors in the cART regimen, in favor of nucleoside reverse transcriptase inhibitors and integrase inhibitors (without cobicistat). After HCT, patients must be closely monitored for development of opportunistic infections (OI), such as cytomegalovirus. Prevention of OI should include prophylactic and pre-emptive antimicrobials. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.
- Author
-
Mei, Matthew G., Siddiqi, Tanya, Al Malki, Monzr M., Salhotra, Amandeep, Aldoss, Ibrahim, Herrera, Alex F., Zain, Jasmine, Popplewell, Leslie L., Chen, Robert W., Rosen, Steven T., Forman, Stephen J., Kwak, Larry, Nademanee, Auayporn P., Budde, Lihua E., Cao, Thai M., Cai, Ji-Lian, Farol, Leonardo T., Chen, Lu, Palmer, Joycelynne, and Song, Joo Y.
- Subjects
- *
MANTLE cell lymphoma , *AUTOTRANSPLANTATION , *STEM cell transplantation , *RITUXIMAB , *TREATMENT effectiveness , *HEALTH outcome assessment , *DISEASE relapse , *THERAPEUTICS - Abstract
High-dose therapy followed by autologous stem cell transplantation (ASCT) can improve outcomes for mantle cell lymphoma (MCL) but is associated with a high incidence of relapse. A retrospective study of 191 MCL patients who underwent ASCT at City of Hope was performed to examine prognostic factors for outcomes after ASCT. For all patients the 5-year overall survival (OS) was 71% (95% confidence interval [CI], 63% to 77%) and progression-free survival (PFS) was 53% (95% CI, 45% to 60%). The 5-year cumulative incidence of relapse was 41% (95% CI, 34% to 48%) with a continuous pattern of relapse events occurring at a median of 2.1 years (range, .2 to 13.4) after ASCT. In multivariate analysis, post-transplant maintenance rituximab was the factor most significantly associated with both OS (relative risk [RR], .17; 95% CI, .07 to .38) and PFS (RR, .25; 95% CI, .14 to .44). For the subset of patients who had positron emission tomography (PET) data available and were in a PET-negative first complete remission at ASCT (n = 105), maintenance rituximab was significantly associated with superior OS (RR, .17; 95% CI, .05 to .59) and PFS (RR, .20; 95% CI, .09 to .43). These results support a benefit with maintenance rituximab for all MCL patients treated with ASCT. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.
- Author
-
Salhotra, Amandeep, Shan, Yuan, Tsai, Ni-Chun, Sanchez, James F., Aldoss, Ibrahim, Ali, Haris, Paris, Tanya, Spielberger, Ricardo, Cao, Thai M., Nademanee, Auayporn, Forman, Stephen J., and Chen, Robert
- Subjects
- *
MANTLE cell lymphoma , *CANCER chemotherapy , *CYCLOPHOSPHAMIDE , *DEXAMETHASONE , *DOXORUBICIN , *VINCRISTINE , *PROGENITOR cells , *THERAPEUTICS - Abstract
Induction regimens for mantle cell lymphoma (MCL) can be categorized into highly intensive regimens containing cytarabine and less intense regimens, such as rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP) or rituximab with bendamustine (R-bendamustine). Prior publications have shown rituximab and hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (R-hyperCVAD) can be associated with stem cell mobilization failures. However, those studies did not include the use of plerixafor as rescue for stem cell mobilization failure. We examined our database of 181 consecutive MCL patients who received upfront therapy from 2005 to 2015 with either R-hyperCVAD or less intense chemotherapy (R-bendamustine and R-CHOP only) regimens to assess impact of frontline chemotherapy on collection of hematopoietic cell progenitors before autologous stem cell transplantation (ASCT). In the preplerixafor era (before August 16, 2009), a significant difference in peripheral blood stem cell (PBSC) collection failure between the R-hyperCVAD (12%) and other chemotherapy (11%) groups was not established. However, in the postplerixafor era, use of R-hyperCVAD chemotherapy was associated with significantly higher rates of hematopoietic progenitor cell collection failures (17%) compared with that observed in the other chemotherapy group (4%; P = .04). The rates of mobilization failure declined to 4% in the postplerixafor era from 11% in the preplerixafor era for patients receiving less intensive chemotherapy. Conversely, the rate of mobilization failure increased in the R-hyperCVAD group from 12% in the preplerixafor era to 17% in the postplerixafor era. Plerixafor does not overcome the negative impact of R-hyperCVAD on PBSC mobilization, and caution is warranted in using R-hyperCVAD in patients with newly diagnosed MCL who are candidates for ASCT. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia.
- Author
-
Aldoss, Ibrahim, Gaal, Karl, Al Malki, Monzr M., Ali, Haris, Nakamura, Ryotaro, Forman, Stephen J., and Pullarkat, Vinod
- Subjects
- *
DASATINIB , *PROTEIN-tyrosine kinase inhibitors , *HEMATOPOIETIC stem cell transplantation , *LYMPHOBLASTIC leukemia treatment , *CYTOMEGALOVIRUSES , *IMMUNOSUPPRESSION , *THERAPEUTICS - Abstract
The tyrosine kinase inhibitor dasatinib is often used after allogeneic hematopoietic cell transplantation to treat minimal residual disease in Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). Colitis, sometimes hemorrhagic, has occasionally been described with the use of dasatinib for both chronic myeloid leukemia and Ph+ ALL. The pathogenesis of dasatinib-induced colitis is unclear but may be related to effects of dasatinib on immune function. We describe a series of 5 patients who had 7 episodes of colitis during dasatinib use. No patient had obvious large granular lymphocytosis in peripheral blood. The histopathologic and immunohistochemical features of these cases were indistinguishable from control cases of gut graft-versus-host disease (GVHD). In all patients symptoms resolved upon discontinuation of dasatinib in addition to therapy with local or low-dose systemic steroids. An additional 3 patients who developed cytomegalovirus (CMV) colitis while on dasatinib therapy were identified and studied. Dasatinib colitis may have an immune-mediated mechanism similar to GVHD, and dasatinib use may be associated with CMV colitis. Awareness of this association is important for avoiding unnecessary intensification of immunosuppression for suspected gut GVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.
- Author
-
Alvarnas, Joseph C., Le Rademacher, Jennifer, Yanli Wang, Little, Richard F., Akpek, Gorgun, Ayala, Ernesto, Devine, Steven, Baiocchi, Robert, Lozanski, Gerard, Kaplan, Lawrence, Noy, Ariela, Popat, Uday, Hsu, Jack, Morris Jr., Lawrence E., Thompson, Jason, Horowitz, Mary M., Mendizabal, Adam, Levine, Alexandra, Krishnan, Amrita, and Forman, Stephen J.
- Subjects
- *
CELL transplantation , *AIDS-related lymphoma , *BONE marrow transplantation , *CARMUSTINE , *CYTARABINE , *AIDS treatment , *THERAPEUTICS - Abstract
Autologous hematopoietic cell transplant (AHCT) for HIV-infected patients is largely limited to centers with HIV-specific expertise. The Blood and Marrow Transplant Clinical Trials Network 0803/AIDS Malignancy Consortium 071 trial is a multicenter phase 2 study of AHCT for patients with HIV-related lymphoma (HRL). Eligible patients had chemotherapy-sensitive relapsed/persistent HRL, were >15 years of age, and had treatable HIV infection. Patients were prepared using carmustine, etoposide, cytarabine, and melphalan and received consistent management of peritransplant antiretroviral treatment. The primary endpoint was 1-year overall survival. Forty-three patients were enrolled; 40 underwent AHCT. Pretransplant HIV viral load was undetectable (<50 copies/mL) in 32 patients (80%); the median CD4 count was 249/mL (range, 39-797). At a median follow-up of 24.8 months, 1-year and 2-year overall survival probabilities were 87.3% (95% confidence interval [CI], 72.1-94.5) and82%(95% CI, 65.9-91), respectively. The probability of 2-year progression-free survival was 79.8% (95% CI, 63.7-89.4). One-year transplant-related mortality was 5.2%. Median time to neutrophil and platelet recovery was 11 days and 18 days, respectively. Nine patients experienced a total of 13 unexpected grade 3-5 adverse events posttransplant (10 grade 3 and 3 grade 4 events). Twenty-two patients had at least 1 infectious episode posttransplant. At 1 year post-AHCT, medianCD41 T-cell count was 280.3 (range, 28.8-1148.0); 82.6% had an undetectable HIV viral load. Trial patients were compared with 151 matched Center for International Bone Marrow Transplant Research controls. Outcomes between HIV-infected patients and controls were not statistically significantly different. HRL patients should be considered candidates for AHCT if they meet standard transplant criteria. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia.
- Author
-
Aldoss, Ibrahim, Al Malki, Monzr M., Stiller, Tracey, Cao, Thai, Sanchez, James F., Palmer, Joycelynne, Forman, Stephen J., and Pullarkat, Vinod
- Subjects
- *
CENTRAL nervous system diseases , *THERAPEUTICS , *LYMPHOBLASTIC leukemia , *CANCER chemotherapy , *HEMATOPOIETIC stem cell transplantation , *MEDICAL research - Abstract
Acute lymphoblastic leukemia (ALL) with a history of central nervous system (CNS) involvement, either at diagnosis or relapse, poses challenges when the decision is made to proceed with allogeneic hematopoietic cell transplantation (alloHCT), as there is no evidence-based consensus on the best peri-transplantation approach to reduce subsequent CNS relapse risk. Here, we retrospectively analyzed outcomes of 87 patients with ALL and a history of CNS involvement who later underwent alloHCT. Patients with pretransplantation CNS involvement had higher risk of CNS relapse after transplantation (2-year CNS relapse: 9.6% versus 1.4%, P < .0001), inferior event-free survival (EFS) (hazard ratio [HR], 1.52; P = .003), and worse overall survival (OS) (HR, 1.55; P = .003) compared with patients without pretransplantation CNS involvement (n = 543). There was no difference in post-transplantation CNS relapse, EFS, or OS among patients presenting with CNS involvement at diagnosis, those with isolated CNS relapse, and those with combined bone marrow and CNS relapse before HCT. Interestingly, neither pretransplantation cranial irradiation, use of total body irradiation–based conditioning, nor post-transplantation prophylactic intrathecal chemotherapy were associated with a reduction of CNS relapse risk after transplantation. Thus, among the patients in the cohort studied, there was no clear benefit of CNS-directed therapy in the peri-transplantation period among patients who had prior CNS involvement and underwent subsequent alloHCT. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Improved Outcomes Using Tacrolimus/Sirolimus for Graft-versus-Host Disease Prophylaxis with a Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant as treatment of Myelofibrosis
- Author
-
Snyder, David S., Palmer, Joycelynne, Gaal, Karl, Stein, Anthony S., Pullarkat, Vinod, Sahebi, Firoozeh, Vora, Nyana, Nakamura, Ryotaro, and Forman, Stephen J.
- Subjects
- *
TACROLIMUS , *RAPAMYCIN , *GRAFT versus host disease , *HEMATOPOIETIC system , *CELL transplantation , *MYELOFIBROSIS , *CYCLOSPORINE , *THERAPEUTICS - Abstract
Allogeneic hematopoietic cell transplantation (HCT) using reduced-intensity conditioning (RIC) regimens is a potentially curative treatment for patients (patients) with myelofibrosis (MF), as we and others have reported. Nonrelapse mortality (NRM) from graft-versus-host disease (GVHD) and other complications has limited the success of this approach. As part of an ongoing prospective research study at City of Hope, a combination of tacrolimus/sirolimus ± methotrexate (MTX) for GVHD prophylaxis has become the standard treatment for our allogeneic HCT patients. In this report, we present results for 23 consecutive patients, including extended follow up for 9 patients previously reported who received cyclosporine (CsA)/mycophenolate moffetil (MMF)±MTX, and the current series of 14 patients who received tacrolimus/sirolimus±MTX, and evaluate the impact of the GVHD prophylaxis regimen on the outcomes. Median follow-up for alive patients was 29.0 months (9.5-97.0). The estimated 2-year overall survival (OS) for the CsA/MMF cohort was 55.6% (confidence interval 36.0, 71.3), and for the tacrolimus/sirolimus cohort it was 92.9% (63.3, 98.8) (P =.047). The probability of grade III or IV acute GVHD (aGVHD) was 60% for the CsA/MMF patients, and 10% for the tacrolimus/sirolimus group (P =.0102). No significant differences were seen for grade II to IV aGVHD in the 2 groups. We conclude that the combination of tacrolimus/sirolimus±MTX for GVHD prophylaxis in the setting of RIC HCT for MF appears to reduce the incidence of severe aGVHD and NRM, and leads to improved OS compared to CSA/MMF±MTX. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
16. Use of Fluid-Ventilated, Gas-Permeable Scleral Lens for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-versus-Host Disease
- Author
-
Takahide, Kikuchi, Parker, Pablo M., Wu, Michael, Hwang, William Y.K., Carpenter, Paul A., Moravec, Carina, Stehr, Barbara, Martin, Paul J., Rosenthal, Perry, Forman, Stephen J., and Flowers, Mary E.D.
- Subjects
- *
KERATOCONJUNCTIVITIS sicca , *CELL transplantation , *IMMUNOSUPPRESSION , *THERAPEUTICS - Abstract
Abstract: Keratoconjunctivitis sicca (KCS) occurs in 40%-60% of patients with chronic graft-versus-host-disease (cGVHD) after allogeneic hematopoietic cell transplantation. Although immunosuppressive therapy is the primary treatment of chronic GVHD, ocular symptoms require measures to improve ocular lubrication, decrease inflammation, and maintain mucosal integrity. The liquid corneal bandage provided by a fluid-ventilated, gas-permeable scleral lens (SL) has been effective in mitigating symptoms and resurfacing corneal erosions in patients with KCS related to causes other than cGVHD. We report outcomes in 9 consecutive patients referred for SL fitting for cGVHD-related severe KCS that was refractory to standard treatments. All patients reported improvement of ocular symptoms and reduced the use of topical lubricants after SL fitting resulting from decreased evaporation. No serious adverse events or infections attributable to the SL occurred. The median Ocular Surface Disease Index improved from 81 (75-100) to 21 (6-52) within 2 weeks after SL fitting, and was 12 (2-53) at the time of last contact, 1-23 months (median, 8.0) after SL fitting. Disability related to KCS resolved in 7 patients after SL fitting. The use of SL appears to be safe and effective in patients with severe cGVHD-related KCS refractory to conventional therapies. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
17. CD123 CAR T cells for the treatment of myelodysplastic syndrome.
- Author
-
Stevens, Brett M., Zhang, Wei, Pollyea, Daniel A., Winters, Amanda, Gutman, Jonathan, Smith, Clayton, Budde, Elizabeth, Forman, Stephen J., Jordan, Craig T., and Purev, Enkhtsetseg
- Subjects
- *
T cells , *MYELODYSPLASTIC syndromes , *THERAPEUTICS , *HEMATOPOIETIC stem cells , *STEM cells - Abstract
• Autologous T cells derived from MDS patients can be successfully transduced and are highly active in multiple functional assays. • A xenograft model was developed in which high-risk MDS specimens engraft to high levels and thus provide an in vivo model for characterization of MDS stem cell behavior. • Autologous T cells are highly active in our xenograft model and selectively target the CD123-positive population. Importantly, CD123 CAR T cells did not exhibit appreciable targeting of normal hematopoietic stem and progenitor cells. Myelodysplastic syndrome (MDS) is a group of heterogeneous disorders caused by ineffective hematopoiesis and characterized by bone marrow dysplasia and cytopenia. Current treatment options for MDS are limited to supportive care, hypomethylating agents, and stem cell transplant. Most patients eventually succumb to the disease or progress to leukemia. Previously, we found that CD123 can be used to delineate MDS stem cells in patients at high risk for MDS and that the CD123-positive population is biologically distinct from normal hematopoietic stem cells. Furthermore, selective targeting of MDS stem cells can dramatically reduce tumor burden in preclinical models. On the basis of these findings, we propose CD123 as a candidate target for chimeric antigen receptor (CAR) T-cell therapy in high-risk MDS patients. To test this concept, we employed a CAR lentiviral vector containing a CD123-specific single-chain variable fragment in combination with the CD28 costimulatory domain, CD3ζ signaling domain, and truncated estimated glomerular filtration rate. Utilizing this system, we illustrate that CD123 CAR can be expressed on both healthy donor and MDS patient-derived T lymphocytes with high efficiency, leading to the successful elimination of MDS stem cells both in vitro and in patient-derived xenografts. These results provide the concept for the use of CD123-targeted CAR T cells as a therapeutic option for patients with MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. 71 - Impact of CYP3A5/CYP2C19 Pharmacogenetics on Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Using Tacrolimus/Sirolimus (Tac/Sir) as Graft Versus Host Disease (GVHD) Prophylaxis.
- Author
-
Khaled, Samer K., Tsai, Ni-Chun, Palmer, Joycelynne, Herzog, Joseph, Gendzekhadze, Ketevan, Senitzer, David, Shayani, Sepideh, Thomas, Sandra, Forman, Stephen J., and Nakamura, Ryotaro
- Subjects
- *
GRAFT versus host disease , *DRUG absorption , *DRUG metabolism , *HEMATOPOIETIC stem cell transplantation , *SINGLE nucleotide polymorphisms , *PHARMACOGENOMICS , *THERAPEUTICS - Published
- 2017
- Full Text
- View/download PDF
19. Tacrolimus/Sirolimus (T/S)-Based GvHD Prophylaxis Does Not Overcome Poor Outcome of HLA Mismatch after Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation.
- Author
-
Al Malki, Monzr M., Gendzekhadze, Ketevan, Karanes, Chatchada, Dagis, Andy, Palmer, Joycelynne, Pham, Anh, Parker, Pablo, Senitzer, David, Nademanee, Auayporn, Forman, Stephen J., and Nakamura, Ryotaro
- Subjects
- *
TACROLIMUS , *RAPAMYCIN , *GRAFT versus host disease , *HLA histocompatibility antigens , *BLOOD donors , *STEM cell transplantation , *HEALTH outcome assessment , *THERAPEUTICS - Published
- 2016
- Full Text
- View/download PDF
20. Older Survivors of Allogeneic Hematopoietic Cell Transplantation (HCT) with Chronic Graft Vs. Host Disease (cGvHD) Demonstrate Higher Risk of Frailty As Compared with Autologous HCT Recipients: A Report from the Bone Marrow Transplant Survivor Study-2.
- Author
-
Arora, Mukta, Sun, Canlan, Ness, Kirsten, Teh, Jennifer Berano, Schad, Amy, Hanby, Cara, Francisco, Liton, Hou, Karen, Wu, Jessica, Kuo, Linus, Armenian, Saro H., Weisdorf, Daniel J., Forman, Stephen J., and Bhatia, Smita
- Subjects
- *
GRAFT versus host disease , *DISEASES in older people , *HEMATOPOIETIC stem cell transplantation , *FRAGILITY (Psychology) , *AUTOGRAFTS , *BONE marrow transplantation , *THERAPEUTICS - Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.